YCharOS Inc.

Our project manager job advert is now live. We are looking for someone to work closely with the members of the Only Good Antibodies community and the stakeholder organisations, to drive better standards of antibody choice and use, and ultimately to accelerate biomedical discovery for the benefit of patients and society. We are looking for someone passionate about improving bioscience with excellent communication skills. We would like someone with an understanding of research antibodies too if possible. If you know anyone who fits the bill please help us to reach out. It is a 0.6FTE role with flexible and hybrid working possible after an induction period. To apply use this link by 16th Sept https://lnkd.in/euEtrafZ

🔬 Struggling to find renewable and selective commercial antibodies for your research needs? Explore our Zenodo community, featuring a comprehensive collection of antibody characterization data for 🎉 over 100 protein targets 🎉 , with several converted to peer-reviewed published articles on our F1000 Gateway. These resources provide the tools you need to advance your research with confidence! Zenodo community ➡ https://lnkd.in/de-S7rFS F1000 gateway➡ https://lnkd.in/eVprw6kd But the work doesn't stop here! The YCharOS team, with the support of our academic and industry partners, is dedicated to scaling up this effort—delivering a higher throughput of high-quality, validated results to improve the reliability of scientific research. #AntibodyValidation #ScientificExcellence #YCharOS #OpenScience #ReliableResearch

A great collaboration between Rachel Harding and YCharOS Inc. led to the characterization of 20 #Huntingtin commercial #antibodies for western blot, immunoprecipitation, and immunofluorescence. Check out this #OpenScience report which empowers users to make informed decisions when selecting high-quality reagents to accelerate Huntington’s Disease research. ▶ https://lnkd.in/gW5afrGR 

🎯 Target of the week: Huntingtin 🎯 In our latest addition to our F1000 gateway, 20 #Huntingtin commercial antibodies were evaluated for their use in western blot, immunoprecipitation and immunofluorescence. Proud to be openly sharing this study to help ensure researchers have access to high-quality reagents to accelerate Huntington’s Disease research.  Explore the publication to identify specific and renewable antibodies for your research! https://lnkd.in/djyBGXrZ Thank you to The Structural Genomics Consortium (SGC) for your collaboration on this study and continuous support! #HuntingtonsDisease #HTT #openscience #antibodycharacterization #reproducibility

We joined the YCharOS Inc. #antibody characteris(z)ation party, and we brought #flowcytometry with us! Congrats to Carolyn Jones and Michael Biddle for pioneering the protocols for flow. Thanks to Riham Ayoubi for helping us to up our western blot and IP game!

Andrew, your analysis of the antibody liability crisis was a wake-up call that inspired the YCharOS Inc. initiative. Grateful to all co-authors, especially Rick Kahn, for their contributions. #openscience

YCharOS Inc. rigorously characterizes commercial antibodies for Western Blot, immunoprecipitation, and immunofluorescence, pinpointing numerous high-performing antibodies. We are highlighting two comprehensive #OpenScience reports which empower users to make informed decisions when selecting the most suitable antibody for their specific needs. 1. High-performing antibodies for Sequestosome-1; an adaptor protein required for selective autophagy and proteasomal degradation: https://lnkd.in/edmdUeWz 2. High-performing antibodies for human Midkine; a growth factor or cytokine involved in cell survival and inflammatory processes: https://lnkd.in/e6aUXYAr

If you work with reagent antibodies, here’s a must read: a new eLife review, co-authored by IPI’s Rob Meijers, about the ongoing “antibody characterization crisis,” initiatives to address the problem and recommendations for stakeholders. Special thanks to our collaborators Harvinder Virk, Carl Laflamme, James Trimmer and Meghan Rego for teeing this off and allowing us to join in! Read the paper here:

Congratulations to Rick Kahn, and all co-authors on their publication of a review on the history of the “antibody characterization crisis”- outlining the scale of the challenge, best practices for antibody validation and actions required from various stakeholders. To read the full eLife feature article: https://lnkd.in/epm5a_e2        We are honoured that our platform was highlighted in this review as a proactive effort in addressing this crisis by adopting antibody characterization procedures to identify renewable and reliable antibodies, while sharing the data openly. A big thank you to our partners, who exemplify the commitment of stakeholders taking an active approach to improving the quality of their research reagents. The impact of our YCharOS platform would not be able to reach such heights without their continuous support: abcam, ABCD Antibodies, ABclonal Technology, Aviva Systems Biology, Bio-Techne, Cell Signaling Technology (CST), Developmental Studies Hybridoma Bank, GeneTex, Inc., Horizon Discovery, Only Good Antibodies community, Proteintech Group, Synaptic Systems GmbH and Thermo Fisher Scientific.

We joined the YCharOS Inc. #antibody characteris(z)ation party, and we brought #flowcytometry with us! Congrats to Carolyn Jones and Michael Biddle for pioneering the protocols for flow. Thanks to Riham Ayoubi for helping us to up our western blot and IP game!